By Fineline Cube 
Hebei Senlang Biotechnology Co., Ltd. announced that its SENL103 autologous T-cell infusion has received clinical approval in China for the treatment of refractory generalized myasthenia gravis (rgMG). This marks a significant milestone in the development of innovative therapies for autoimmune diseases.
SENL103: BCMA CAR-T Cell Therapy
SENL103 is a BCMA CAR-T cell therapy utilizing genetically engineered T cells to target cells with high expression of BCMA. Previously, SENL103 had been approved for clinical trials in treating relapsed or refractory multiple myeloma (RRMM). This new approval expands its potential therapeutic applications to include rgMG.
Mechanism and Applications
SENL103 works by engineering a patient’s own T cells to express chimeric antigen receptors (CARs) targeting BCMA, which is commonly overexpressed in certain cancers and autoimmune conditions. By redirecting the patient’s immune system, SENL103 aims to provide a novel treatment option for patients with limited therapeutic alternatives.-Fineline Info & Tech